[
  {
    "ts": null,
    "headline": "Why Pfizer (PFE) Dipped More Than Broader Market Today",
    "summary": "Pfizer (PFE) concluded the recent trading session at $25.77, signifying a -0.46% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=aa5879c5a843824f4bff55ecfe3fd5fb306dc5882e0699a9552255af61ff0704",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734648320,
      "headline": "Why Pfizer (PFE) Dipped More Than Broader Market Today",
      "id": 132062132,
      "image": "https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) concluded the recent trading session at $25.77, signifying a -0.46% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=aa5879c5a843824f4bff55ecfe3fd5fb306dc5882e0699a9552255af61ff0704"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors despite losses on the day",
    "summary": "Pfizer Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=b347b5dc61375d012bcc7b35e3a9edb299775db23dce24e31862e9fcb76f638a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734626340,
      "headline": "Pfizer Inc. stock outperforms competitors despite losses on the day",
      "id": 132066910,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=b347b5dc61375d012bcc7b35e3a9edb299775db23dce24e31862e9fcb76f638a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts",
    "summary": "NEW YORK, December 19, 2024--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EST on Tuesday, February 4, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter and Full Year 2024 Performance Report, to be issued that morning.",
    "url": "https://finnhub.io/api/news?id=bdb813d9e82d5e48080571c74b3b436abd2844223dbecaa06857c3a0425b315f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734620400,
      "headline": "Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts",
      "id": 132053557,
      "image": "https://media.zenfs.com/en/business-wire.com/716f9c2aadc12d8adaed211dd84daaf0",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, December 19, 2024--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EST on Tuesday, February 4, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter and Full Year 2024 Performance Report, to be issued that morning.",
      "url": "https://finnhub.io/api/news?id=bdb813d9e82d5e48080571c74b3b436abd2844223dbecaa06857c3a0425b315f"
    }
  },
  {
    "ts": null,
    "headline": "Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development",
    "summary": "Sangamo Therapeutics, Inc. has groundbreaking treatments for neuropathic pain and Hemophilia A. Click for my updated look at SGMO stock prospects.",
    "url": "https://finnhub.io/api/news?id=101f2644d0b93f40d098c752f5b7f54331a86be857a34927f6d02aa5f4ad2670",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734619681,
      "headline": "Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development",
      "id": 132056177,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2189638512/image_2189638512.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Sangamo Therapeutics, Inc. has groundbreaking treatments for neuropathic pain and Hemophilia A. Click for my updated look at SGMO stock prospects.",
      "url": "https://finnhub.io/api/news?id=101f2644d0b93f40d098c752f5b7f54331a86be857a34927f6d02aa5f4ad2670"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics: Competition Fears Are Exaggerated",
    "summary": "Viking Therapeutics shows promise with weight loss drug VK2735 and potential in NASH treatment, making it a potential takeover target. Read more on VKTX here.",
    "url": "https://finnhub.io/api/news?id=f68f0ab502abbaa2855584a34573a73d3d30cef19848c50d38bb6cd463a08728",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734609342,
      "headline": "Viking Therapeutics: Competition Fears Are Exaggerated",
      "id": 132053590,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1719209231/image_1719209231.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Viking Therapeutics shows promise with weight loss drug VK2735 and potential in NASH treatment, making it a potential takeover target. Read more on VKTX here.",
      "url": "https://finnhub.io/api/news?id=f68f0ab502abbaa2855584a34573a73d3d30cef19848c50d38bb6cd463a08728"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26?",
    "summary": "Shares of Pfizer (NYSE: PFE) recently marched higher in response to a dividend payout raise and a forward-looking presentation.  In response to Pfizer's latest guidance update, BMO Capital analyst Evan Seigerman reiterated an outperform rating and a $36 per-share price target.  If Pfizer stock reaches Seigerman's target, investors who buy at recent prices could see their principal investments gain about 37% in the year ahead.",
    "url": "https://finnhub.io/api/news?id=fdf617615a9f4ab90f55310979ae48b0419cd32285bf40451e7e841de566bec5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734606420,
      "headline": "Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26?",
      "id": 132053559,
      "image": "https://g.foolcdn.com/editorial/images/801397/investor-looks-at-financial-chart-on-laptop-getty.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Shares of Pfizer (NYSE: PFE) recently marched higher in response to a dividend payout raise and a forward-looking presentation.  In response to Pfizer's latest guidance update, BMO Capital analyst Evan Seigerman reiterated an outperform rating and a $36 per-share price target.  If Pfizer stock reaches Seigerman's target, investors who buy at recent prices could see their principal investments gain about 37% in the year ahead.",
      "url": "https://finnhub.io/api/news?id=fdf617615a9f4ab90f55310979ae48b0419cd32285bf40451e7e841de566bec5"
    }
  },
  {
    "ts": null,
    "headline": "Impax Global Opportunities Fund Q3 2024 Commentary",
    "summary": "The Global Opportunities Fund outperformed its benchmark in the third quarter of 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=489f8a8d0be4cc8799e506a8cd262176e2ebeb9936482a87f98824308f7a526b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734604200,
      "headline": "Impax Global Opportunities Fund Q3 2024 Commentary",
      "id": 132052294,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2170698203/image_2170698203.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "The Global Opportunities Fund outperformed its benchmark in the third quarter of 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=489f8a8d0be4cc8799e506a8cd262176e2ebeb9936482a87f98824308f7a526b"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s RSV antibody could soon paddle into the rough waters of a crowded market",
    "summary": "A new antibody from Merck would join a market teeming with new entries, but plenty of regulatory and financial uncertainty.",
    "url": "https://finnhub.io/api/news?id=a613b84ce88b1b8e0dc13b6f79749c525cdb020c8b612d9ab747fa678e682bd5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734595200,
      "headline": "Merck’s RSV antibody could soon paddle into the rough waters of a crowded market",
      "id": 132052818,
      "image": "https://imgproxy.divecdn.com/LWPxHVUcDkZMiMUsy0TWcd-p9KYWrzM3Siin1LumbOc/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjEwOTMxMjkxXzEuanBn.webp",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A new antibody from Merck would join a market teeming with new entries, but plenty of regulatory and financial uncertainty.",
      "url": "https://finnhub.io/api/news?id=a613b84ce88b1b8e0dc13b6f79749c525cdb020c8b612d9ab747fa678e682bd5"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Had a Dismal Year. Therein Lies Opportunity, Says This Analyst.",
    "summary": "Healthcare Stocks Had a Dismal Year. Therein Lies Opportunity, Says This Analyst.",
    "url": "https://finnhub.io/api/news?id=aa7ea5476f27dfcde053969034f4c235fdcbedf92bdf515eef27d73e6559dadd",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734566700,
      "headline": "Healthcare Stocks Had a Dismal Year. Therein Lies Opportunity, Says This Analyst.",
      "id": 132064401,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Healthcare Stocks Had a Dismal Year. Therein Lies Opportunity, Says This Analyst.",
      "url": "https://finnhub.io/api/news?id=aa7ea5476f27dfcde053969034f4c235fdcbedf92bdf515eef27d73e6559dadd"
    }
  }
]